ライフサイエンスコーパス: renal transplant

1 olycystic kidney disease (APKD) in need of a renal transplant.

2 one required hemodialysis and four underwent renal transplant.

3 antibodies induced a recurrence of MN in the renal transplant.

4 tes lifelong immunosuppressive therapy after renal transplant.

5 eas transplant is performed some years after renal transplant.

6 evidence of dialysis (lasting >6 months) or renal transplant.

7 sis in a 66-year-old man who had undergone a renal transplant.

8 junction with either cadaveric or live donor renal transplant.

9 ent GFR reading at a time point 1 year after renal transplant.

10 ving donor (n=427) or deceased donor (n=548) renal transplant.

11 Receipt of a renal transplant.

12 n fibroblast growth factor-23/KLOTHO axis in renal transplants.

13 rior when compared with well HLA-matched DBD renal transplants.

14 DGF) in patients who received deceased donor renal transplants.

15 cellent visualization of vascular anatomy of renal transplants.

16 oninvasive tool to detect high risk of AR of renal transplants.

17 to be a significant impediment to access to renal transplants.

18 vs. 120.2 +/-17.9, P=0.0014) were higher in renal transplants.

19 negative long-term outcome in patients with renal transplants.

20 ls in patients may thus improve prognosis of renal transplants.

21 One hundred thirteen consecutive renal transplant 2D and 3D ultrasound examinations were

22 ] age, 56 [19] years), 177 (53.8%) underwent renal transplant; 58 (17.6%), heart transplant; 54 (16.4

23 Ureteral complications of renal transplants after living donor nephrectomy are unc

24 participating in the Assessment of LEscol in Renal Transplant (ALERT) study.

25 the latest evidence for management of RCC in renal transplant allografts.

26 16.3% of renal transplant alone patients required nephrectomy at

27 to be safe and effective for patients after renal transplant and is a promising treatment regimen fo

28 protective role in response to injury after renal transplant and, presumably, in other forms of acut

29 Seven patients received a renal transplant, and among those whose underlying clona

30 4-5 at baseline, and those who had undergone renal transplant before exposure.

31 atch) recipients who received deceased donor renal transplants between December 2009 and November 201

32 and molecular biology, we examined protocol renal transplant biopsies from 19 recipients with HIV-1

33 munohistochemistry revealed US28 in 31 of 34 renal transplant biopsies from HCMV-seropositive donors.

34 Thirty-nine renal transplant biopsies from patients with de novo don

35 Renal transplant biopsies with acute tubular necrosis de

36 However, the associations of TRIs in renal transplant biopsy specimens are not known.

37 n, and heat shock protein 47, for ABMR in 53 renal transplant biopsy specimens, including 20 ABMR spe

38 Renal transplant candidates (RTC) with latent tuberculos

39 ancer may be more harmful than protective in renal transplant candidates because it does not appear t

40 of anti-HLA sensitized and highly sensitized renal transplant candidates on waiting lists, and the pr

41 Renal transplant candidates with high levels of donor-sp

42 ion (KPD) has emerged as a viable option for renal transplant candidates with incompatible living don

43 o specific guidelines exist for screening in renal transplant candidates.

44 A prospective, observational renal transplant cohort (n = 185; minimum, 5-year follow

45 opsies from a prospective, multicenter adult renal transplant cohort (n=111).

46 quenced the entire mitochondrial genome in a renal transplant cohort of 64 individuals, using next-ge

47 ninety-seven subjects referred for a primary renal transplant completed the questionnaire.

48 cause the vasculature is affected in chronic renal transplant dysfunction, US28 may provide a potenti

49 ients not yet on dialysis or for those after renal transplant, early institution of recombinant human

50 tients >/=18 years of age undergoing primary renal transplant evaluation during a 10-year period.

51 ospective study of 1,597 subjects undergoing renal transplant evaluation from June 1, 2006, to March

52 rs associated with rate of completion of the renal transplant evaluation were analyzed using a retros

53 Renal transplant failure has a devastating impact on pat

54 Renal transplant failure has a profound impact on recipi

55 Patients returning to dialysis therapy after renal transplant failure have high morbidity and retrans

56 structured interviews in the first year post-renal transplant failure.

57 arity as a barrier to successful outcomes in renal transplants for African Americans has been well de

58 Five patients had failed at least 1 previous renal transplant from aHUS.

59 ective study of 594 adults with PCKD who had renal transplants from 1994 to 2014.

60 nterstitial fibrosis may occur abnormally in renal transplants from donations after uncontrolled circ

61 patients, 195 HCV+ recipients (R+) received renal transplants from HCV+ donors (D+), in contrast to

62 Adverse events were scarce; renal transplant function and proteinuria remained stabl

63 Renal transplant glomerulitis (G) is associated with acu

64 66.9 [12.5] years), and 2980 patients in the renal transplant group (27.3% women; 72.7% men; mean [SD

65 in the stage 5D CKD group, and 65.2% in the renal transplant group received in-hospital reperfusion

66 The renal transplant group was more likely to receive reperf

67 isk-adjusted in-hospital mortality among the renal transplant group with STEMI was markedly lower com

68 ients in the non-CKD, stage 5D CKD, or prior renal transplant groups.

69 has progressed to functional impairment of a renal transplant have been defined in clinical biopsy sp

70 ealign the priorities of clinical trials for renal transplant immunosuppression with the current unme

71 nts, 31 women and 24 men, who underwent HLAi renal transplant in our center from September 2005 to Se

72 change in pretreatment protocol will improve renal transplants in patients receiving LDK.

73 rinary CXC chemokine ligand (CXCL)10 detects renal transplant inflammation noninvasively, but has lim

74 Renal transplant is the treatment of choice for patients

75 splantation among individuals with two prior renal transplants is not described in the literature, an

76 dy-mediated rejection is a leading cause for renal transplant loss.

77 Adults who underwent live donor renal transplant (LRT) + simultaneous BN (SBN) from Augu

78 compared outcomes in pregnancies fathered by renal transplant men per whether they had been exposed t

79 a from the Norwegian Renal Registry with all renal transplanted men alive between January 1, 1995 and

80 During the given time, 230 immunosuppressed renal transplanted men fathered 350 children (155 on MPA

81 (Eld) (>/=60 years) recipients are receiving renal transplants more frequently.

82 ed 1,679 adult, deceased donor, single-organ renal transplants occurring between 2000 and 2012.

83 CKD cohort (n=104), identified the effect of renal transplant on serum TMAO concentration in a subset

84 Three groups were analyzed: renal transplant-only recipients (tx alone), recipients

85 In children, poorly HLA-matched LD renal transplant outcomes are not inferior when compared

86 jor source of HO-1 and higher levels improve renal transplant outcomes.

87 nsplant immunosuppression is known to affect renal transplant outcomes.

88 nd prognostic values of this measurement for renal transplant pathology and outcome remain unclear.

89 reviously unknown poxvirus rash illness in a renal transplant patient.

90 ion in peripheral blood mononuclear cells of renal transplant patients (r=0.91, P<0.001).

91 which is currently a major cause of death in renal transplant patients (RTRs).

92 ctional, interview study was conducted among renal transplant patients aged 20 to 30 years.

93 ctive observational and database analysis of renal transplant patients and a physician questionnaire

94 r) in a large, inclusive survey (n = 172) in renal transplant patients at a single institution.

95 xpression data in 558 blood samples from 436 renal transplant patients collected across eight transpl

96 chocardiography) assessment were done in 165 renal transplant patients during the first year and afte

97 Renal transplant patients have been shown to have a high

98 trospective, case-control study examined 120 renal transplant patients in a VL endemic area.

99 Furthermore, analysis of data from 46,691 renal transplant patients in the United Network for Orga

100 Forty renal transplant patients on Tac BID were converted on a

101 levels of catalytic IgG in a large cohort of renal transplant patients over a 2-y period.

102 of predicted alloimmune quiescence in stable renal transplant patients receiving long-term immunosupp

103 Paricalcitol administration to renal transplant patients significantly reduced intact p

104 monitoring (ABPM) for risk stratification in renal transplant patients still remains poorly defined.

105 We evaluated antibody binding of waitlisted renal transplant patients to 3 glycan knockout (KO) pig

106 A retrospective study in all renal transplant patients treated with tacrolimus at our

107 Twenty renal transplant patients were included in this retrospe

108 Seventy-five renal transplant patients were included, and six of them

109 and HLA-DQ antigens were determined for 703 renal transplant patients who had no detectable donor-sp

110 y and safety of sofosbuvir and ledipasvir in renal transplant patients with chronic HCV infection.

111 non-smokers were included (40 CsA-medicated renal transplant patients with GO [GO+; n = 20] or witho

112 y, no guidelines exist for the management of renal transplant patients with impaired glucose toleranc

113 In preliminary studies, adult renal transplant patients with normal histology (n = 5),

114 om a prospective, observational cohort of 59 renal transplant patients with surveillance or indicatio

115 formulation is similar to Prograf in stable renal transplant patients, but data in de novo patients

116 converting from Tac BID to Tac QD in stable renal transplant patients, especially in patients with t

117 converting from Tac BID to Tac QD in stable renal transplant patients, especially in patients with t

118 In renal transplant patients, TCF7L2 rs7903146 is strongly

119 In renal transplant patients, the prevalence of nocturnal h

120 , and kidney biopsies were collected from 48 renal transplant patients.

121 d GC-MS-based metabolomic study on urines of renal transplant patients.

122 y of monitoring immunosuppressive therapy in renal transplant patients.

123 oming the standard of care for KS arising in renal transplant patients.

124 ion profile, a finding that was confirmed in renal transplant patients.

125 ey allograft survival affecting up to 15% of renal transplant patients.

126 L10 for detecting alloimmune inflammation in renal transplant patients.

127 iovascular risk attributable to BP burden in renal transplant patients.

128 udy, we assessed the outcome of all (n = 95) renal transplanted patients with pretransplant cancer di

129 ABO-incompatible renal transplant performed with antibody removal and con

130 pective review of 7 consecutive living donor renal transplants performed using the RF technique was p

131 The 7 preceding living donor renal transplants performed using the standard arterial

132 then studied in a larger, prospective adult renal transplant population (n = 148 urines from n = 133

133 C virus (HCV) infection is prevalent in the renal transplant population but direct acting antiviral

134 The prevalent renal transplant population presents an opportunity to o

135 mentation of vitamin D, close to half of the renal transplant population was still deficient.

136 rrogate of kidney disease progression in the renal transplant population, as it is in proteinuric nep

137 The other control group comprised the entire renal transplanted population in Uppsala.

138 We included 310 adult renal transplants receiving twice-daily tacrolimus throu

139 A renal transplant recipient in her 60s presented with a h

140 , we describe the case of a 63-year-old male renal transplant recipient with a remote history of pulm

141 t a rare survival case of isolated GITB in a renal transplant recipient, occurring seven years after

142 Twenty renal transplant recipients (10 rituximab-treated, 10 pl

143 ed 12-hour everolimus (EVL) PK in 16 elderly renal transplant recipients (all whites; 10 men; mean ag

144 epidemiology in a large cohort of pediatric renal transplant recipients (n = 242) and assessed the i

145 mortality, and graft failure in a cohort of renal transplant recipients (n=495, median follow-up 7.0

146 a single-center, prospective cohort study of renal transplant recipients (N=81), urinary clusterin wa

147 ejection (BPAR) in 216 moderately sensitized renal transplant recipients (negative flow crossmatch an

148 pathy (BKVN), affects 5% to 16% of pediatric renal transplant recipients (PRTR).

149 intake, with graft failure and mortality in renal transplant recipients (RTR) and potential effect m

150 e potential role of SDMA as a risk marker in renal transplant recipients (RTR) has not been investiga

151 igh-risk, donor-positive/recipient-negative, renal transplant recipients (RTR).

152 rparathyroidism is reported in 10% to 66% of renal transplant recipients (RTR).

153 g is a risk factor for poor late outcomes in renal transplant recipients (RTR).

154 nd its impact on renal function in pediatric renal transplant recipients (RTR).

155 tabolites with cardiometabolic parameters in renal transplant recipients (RTRs) and analyzed their pr

156 f pyridoxal 5'-phosphate (PLP) are common in renal transplant recipients (RTRs) and confer increased

157 Renal transplant recipients (RTRs) have commonly been ur

158 cancer (NMSC) is substantially higher among renal transplant recipients (RTRs) than in the general p

159 on viral infections that affect up to 10% of renal transplant recipients (RTRs), causing allograft dy

160 Arterial hypertension (HT) is common in renal transplant recipients (RTRs).

161 re cardiovascular morbidity and mortality in renal transplant recipients (RTRs).

162 centrations of pyridoxal-5-phospate (PLP) in renal transplant recipients (RTRs).

163 ssociated with an increased risk of death in renal transplant recipients (RTRs).

164 ral blood monocyte cells and CD3+ T cells of renal transplant recipients (RTX) receiving tacrolimus (

165 pheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontransplant contro

166 010 and 2011) influenza vaccine in 23 stable renal transplant recipients and 22 healthy controls.

167 l carcinoma is the most common malignancy in renal transplant recipients and a major cause of morbidi

168 We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with T

169 Renal transplant recipients and dialysis patients were e

170 These data will further inform prospective renal transplant recipients and donors during pretranspl

171 on accounts for around half of all pediatric renal transplant recipients and results in improved rena

172 reshold value likely needs to be lowered for renal transplant recipients and supports continued use o

173 sured in a longitudinal cohort of 699 stable renal transplant recipients and the associations of T50

174 cells obtained from a new cohort of tolerant renal transplant recipients and those from age- and sex-

175 entify clinically significant de novo DSA in renal transplant recipients and to define the properties

176 Approximately only 50% of renal transplant recipients are alive at 10 years due to

177 or the prevention of rejection in sensitized renal transplant recipients are not well established.

178 In Brazil, most renal transplant recipients are on social security benef

179 differentiated CD8(+) T cells would identify renal transplant recipients at elevated SCC risk.

180 finding could help in the identification of renal transplant recipients at high risk of this cancer,

181 In a population of 48 stable renal transplant recipients at least 6 months from time

182 approximately 800 patients in the cohort of renal transplant recipients at our institution, 15 subje

183 ogic and infection-related parameters in 499 renal transplant recipients between 1 month and 33 years

184 ystems patient and claims data for all adult renal transplant recipients between 2000 and 2010 with c

185 be the effects of AL induction therapy on AA renal transplant recipients beyond the first posttranspl

186 Melanoma risk factors and incidence in renal transplant recipients can inform decision making f

187 based immunosuppressive treatment in de novo renal transplant recipients caused marginal changes in L

188 SCCs (13) from renal transplant recipients displayed the same telomere

189 tation of PTTB and may show delayed onset in renal transplant recipients due to the use of lower dose

190 lled study using C1-INH in highly sensitized renal transplant recipients for prevention of AMR.

191 arge national data registry used a cohort of renal transplant recipients from the United States Renal

192 Renal transplant recipients had greater risk of developi

193 ugh the proportion of elderly patients among renal transplant recipients has increased, pharmacokinet

194 Research in renal transplant recipients has suggested that pancreati

195 There is evidence that renal transplant recipients have accelerated atheroscler

196 We analyzed a prospective cohort of renal transplant recipients having routine EBV PCR surve

197 A previous GWAS performed in 300 renal transplant recipients identified two SNPs (rs38113

198 We describe the results of 11 ABOi pediatric renal transplant recipients in the 2 largest centers in

199 or the progression of glucose intolerance in renal transplant recipients in the late posttransplant p

200 This study puts focus on renal transplant recipients in their 80th year or longer

201 Hypertension in renal transplant recipients is common and ranges from 50

202 dity associated with malignancy in long-term renal transplant recipients is due to cutaneous squamous

203 ment of hepatitis C virus (HCV) infection in renal transplant recipients is possible, but limited dat

204 ave been reported in ABO-incompatible (ABOi) renal transplant recipients managed solely with antibody

205 use of hereditary and acquired risk factors, renal transplant recipients manifest features of a chron

206 ) formulation with the original (Prograf) in renal transplant recipients older than 60 years.

207 Homoarginine was measured in 829 renal transplant recipients participating in the placebo

208 estimated glomerular filtration rate, and 23 renal transplant recipients referred for parathyroidecto

209 Notably, BP treatment goals for renal transplant recipients remain an enigma because the

210 proteinuria, diabetes, or CKD stages 1-4 or renal transplant recipients reporting >/=10 ESRD events

211 Our data indicate that elderly renal transplant recipients starting EVL 1 month after t

212 carcinoma development in long-term, at-risk renal transplant recipients than previously identified c

213 was tested on >1000 samples from a cohort of renal transplant recipients to assess its performance in

214 We performed a retrospective analysis of renal transplant recipients treated with rapamycin from

215 , point to the need for careful follow-up of renal transplant recipients undergoing intravitreal ther

216 We recommend that in renal transplant recipients undergoing therapy with intr

217 retrospective study in which 76 non-diabetic renal transplant recipients underwent oral glucose toler

218 d standard (iohexol plasma clearance) in 193 renal transplant recipients using concordance correlatio

219 pared cancer incidence in PKD versus non-PKD renal transplant recipients using Poisson regression, an

220 Whether outcomes of MI differ among renal transplant recipients vs patients with stage 5D CK

221 tcomes of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CKD group or

222 ulations, plasma neopterin, and cytokines in renal transplant recipients was investigated in this stu

223 ousand three hundred seventy-eight pediatric renal transplant recipients were analyzed; 804 (58%) rec

224 Renal transplant recipients were classified as never, fo

225 Renal transplant recipients were included if they were a

226 Five hundred seventy-seven consecutive renal transplant recipients were included.

227 A total of 5983 renal transplant recipients were included.

228 Renal transplant recipients were randomized to receive e

229 Eighty renal transplant recipients were randomized, and 78 were

230 etermine risk factors and characteristics of renal transplant recipients who develop melanoma.

231 We retrospectively identified 59 renal transplant recipients who developed dnDSA and had

232 We report 2 cases of renal transplant recipients who developed significant al

233 Renal transplant recipients who experience delayed graft

234 Adult renal transplant recipients who had symptomatic chronic

235 ulating anti-PLA2R antibodies in a cohort of renal transplant recipients who prospectively developed

236 th a functioning graft (DWFG) is affected in renal transplant recipients who receive prophylaxis for

237 We report our experience treating 43 renal transplant recipients with 4 different DAA regimen

238 A cohort of 596 renal transplant recipients with 50,011 serial tacrolimu

239 Twelve renal transplant recipients with aHUS-related end-stage

240 57 renal transplant recipients with and 53 without previous

241 Renal transplant recipients with and without previous sq

242 In renal transplant recipients with CKD stages 4 to 5T, pat

243 Renal transplant recipients with de novo DSA (dDSA) expe

244 es from 1 patient with JCPyVAN and 20 stable renal transplant recipients with JCPyV viruria was attem

245 Renal transplant recipients with otherwise unexplainable

246 However, it is not known whether renal transplant recipients with PKD have an increased r

247 l but not death-censored renal graft loss in renal transplant recipients with PTDM.

248 deling and mineral loss, and reduced eGFR in renal transplant recipients with secondary hyperparathyr

249 In-hospital mortality rates in renal transplant recipients with STEMI are more favorabl

250 Among renal transplant recipients with STEMI, the use of reper

251 t study and case-control study in 50 de novo renal transplant recipients, 50 chronic kidney disease (

252 , we systematically analyzed HDL from stable renal transplant recipients, according to graft function

253 ed in 2,851 Caucasian and 570 Afro-Caribbean renal transplant recipients, and in 236 transplant recip

254 CPyV) is reactivated in approximately 20% of renal transplant recipients, and it may rarely cause JCP

255 ct development of squamous cell carcinoma in renal transplant recipients, and undertook a prospective

256 isease remains the leading cause of death in renal transplant recipients, but the underlying causativ

257 In moderately sensitized deceased donor renal transplant recipients, induction with ATG is assoc

258 apy for Pneumocystis pneumonia prevention in renal transplant recipients, reported adverse drug react

259 compartments from 20 HCMV-infected patients (renal transplant recipients, stem cell transplant recipi

260 pective cohort study of 2749 adult Norwegian renal transplant recipients, transplanted between 1999 a

261 ction against early acute rejection in black renal transplant recipients, whereas sensitized patients

262 (PVAN) occurs in a significant percentage of renal transplant recipients, with BK virus reactivation

263 s were found in urine samples from 19 stable renal transplant recipients, with JCPyV quasispecies det

264 ed with better patient and graft survival in renal transplant recipients.

265 ffness, oxidative stress, or inflammation in renal transplant recipients.

266 fness, oxidative stress, and inflammation in renal transplant recipients.

267 transplant immune surveillance for pediatric renal transplant recipients.

268 ally in the increasing population of elderly renal transplant recipients.

269 ogression of kidney failure and mortality in renal transplant recipients.

270 and OGTT were performed in 1,619 nondiabetic renal transplant recipients.

271 alent to the original formulation in elderly renal transplant recipients.

272 s, correlates with delayed graft function in renal transplant recipients.

273 curs in 16% to 20% of low-risk, CMV-positive renal transplant recipients.

274 t-line Pneumocystis pneumonia prophylaxis in renal transplant recipients.

275 onitoring in a large, multi-ethnic cohort of renal transplant recipients.

276 A antibodies (dnDSA) may cause graft loss in renal transplant recipients.

277 nt in the patient with JCPyVAN and in stable renal transplant recipients.

278 ependent of plasma HDL cholesterol levels in renal transplant recipients.

279 rence in this cohort of long-term, high-risk renal transplant recipients.

280 withdrawal has been demonstrated in selected renal-transplant recipients with haematopoietic chimeris

281 prospective Mycophenolic Acid Observational Renal Transplant registry.

282 8-mediated T-cell costimulation and prevents renal transplant rejection.

283 Renal transplants remain a medical challenge, because th

284 Renal transplant resolves HPT in 56.9% of patients at 2

285 Renal transplant-specific risk factors have not been est

286 es after deceased donor but not living donor renal transplants, thus donor death and organ preservati

287 mother had previously presented with a post-renal transplant TMA.

288 Three prospective pig-to-baboon renal transplants using kidneys from swine delivered by

289 dimensional (3D) ultrasound in evaluation of renal transplant vasculature compared to 2-dimensional (

290 of hemodialysis in 2006 to placement on the renal transplant waiting list or to December 31, 2009.

291 on, size, and ownership) on placement on the renal transplant waiting list was evaluated by multi-lev

292 on with subsequent prioritized allocation of renal transplant was endorsed in selected cases.

293 y exposure posed a concern, as our patient's renal transplant was identified as the infection source.

294 Renal transplant was marked by a drastic decrease in lev

295 rospective chart review of consecutive adult renal transplants was conducted between 2006 and 2014.

296 Fifty pediatric renal transplants were performed from 1/2009-12/2014.

297 A total of 127,355 adult renal transplants were performed.

298 Two patients who had received renal transplants while inpatients in an adjacent ward d

299 Patients with renal transplants who received a diagnosis of melanoma a

300 d proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism.